Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss Eton Pharmaceuticals Q3 2025 results: A mixed quarter with a 7.6% revenue beat but a miss on earnings per share.
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026.
3 Stocks Insiders Are Buying Heavily In October 2024, And Why Should investors add these stocks on their watchlist? Insider buys suggest so.
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
